A novel function of Siglec-9 A391C polymorphism on T cell receptor signaling

International Archives of Allergy and Immunology

Volumn 154, Issue 2, 2011, Pages 111-118

  Cheong, Kyung Ah ^a   Chang, Yoon Seok ^b   Roh, Joo Young ^c   Kim, Bum Jun ^d   Kim, Myung Nam ^d   Park, Youn Min ^e   Park, Hai Jin ^f   Kim, Nam Doo ^g   Lee, Chang Hoon ^h   Lee, Ai Young ^a  

^a Dongguk University Ilsan Hospital   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Gachon University   (South Korea)

^d Chung Ang University   (South Korea)

^e The Catholic University of Korea College of Medicine   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g Equispharm Co Ltd   (South Korea)

^h Dongguk University   (South Korea)

Author keywords

A391C polymorphism; Homology structure model; Red blood cell binding; Siglec 9; T cell receptor mediated signaling

Indexed keywords

IMMUNOGLOBULIN; INTERLEUKIN 2; LECTIN; PROTEIN KINASE ZAP 70; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN 9; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL BINDING; CONTROLLED STUDY; ERYTHROCYTE; HUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE;

ANTIGENS, CD; BLOTTING, WESTERN; ERYTHROCYTES; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2; JURKAT CELLS; LECTINS; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; N-ACETYLNEURAMINIC ACID; PHOSPHORYLATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, ANTIGEN, T-CELL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFECTION; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 77956070550     PISSN: 10182438     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320225     Document Type: Article

References (30)

1. Powell LD, Varki A: I-type lectins. J Biol Chem 1995; 270: 14243-14246.
2. Crocker PR, Varki A: Siglecs, sialic acids and innate immunity. Trends Immunol 2001; 22: 337-342.
3. Taylor VC, Buckley CD, Douglas M, Cody AJ, Simmons DL, Freeman SD: The myeloidspecific sialic acid-binding receptor, CD33, associates with the proteintyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem 1999; 274: 11505-11512.
4. Paul SP, Taylor LS, Stansbury EK, McVicar DW: Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood 2000; 96: 483-490.
5. Avril T, Floyd H, Lopez F, Vivier E, Crocker PR: The membrane-proximal immunoreceptor tyrosine based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells. J Immunol 2004; 173: 6841-6849.
6. Alphey MS, Attrill H, Crocker PR, van Aalten DM: High resolution crystal structures of Siglec-7: insights into ligand specificity in the Siglec family. J Biol Chem 2003; 278: 3372-3377.
7. von Gunten S, Yousefi S, Seitz M, Jakob SM, Schaffner T, Seger R, et al: Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood 2005; 106: 1423-1431.
8. von Gunten S, Schaub A, Vogel M, Stadler BM, Miescher S, Simon HU: Immunologic and functional evidence for anti-Siglec-9 autoantibodies in intravenous immunoglobulin preparations. Blood 2006; 108: 4255-4259.
9. Kazatchkine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-755.
10. Emmi L, Chiarini F: The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders. Neurol Sci 2002; 23(suppl 1):S1-S8.
11. Jolles S, Sewell WA, Misbah SA: Clinical uses of intravenous immunoglobulin. Clin Exp Immunol 2005; 142: 1-11.
12. Zhang JQ, Nicoll G, Jones C, Crocker PR: Siglec-9, a novel sialic acid binding member of the immunoglobulin superfamily expressed broadly on human blood leukocytes. J Biol Chem 2000; 275: 22121-22126.
13. Nicoll G, Ni J, Liu D, Klenerman P, Munday J, Dubock S, Mattei MG, Crocker PR: Identification and characterization of a novel siglec, siglec-7, expressed by human natural killer cells and monocytes. J Biol Chem 1999; 274: 34089-34095.
14. Ando M, Tu W, Nishikima K, Iijima S: Siglec-9 enhances IL-10 production in macrophages via tyrosine-based motifs. Biochem Biophysi Res Commun 2008; 369: 878-883.
15. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin- 10 receptor. Annu Rev Immunol 2001; 19: 683-765.
16. Ikehara Y, Ikehara S, Paulson J: Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem 2004; 279: 43117-43125.
17. Nguyen DH, Hurtado-Ziola N, Gagneux P, Varki A: Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci USA 2006; 103: 7765-7770.
18. Crocker PR, Paulson JC, Varki A: Siglecs and their roles in the immune system. Nat Rev Immunol 2007; 7: 255-266.
19. Yamaji T, Teranishi T, Alphey MS, Crocker PR, Hashimoto Y: A small region of the natural killer cell receptor, Siglec-7, is responsible for its preferred binding to alpha 2,8-disialyl and branched alpha 2,6-sialyl residues: a comparison with Siglec-9. J Biol Chem 2002; 277: 6324-6332.
20. Gamblin SJ, Haire LF, Russel RJ, Stevens DJ, Xiao B, Ha Y, Vasisht N, Steinhauer DA, Daniels RS, Elliot A, Wiley DC, Skehel JJ: The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 2004; 303: 1838-1842.
21. Williams BL, Irvin BJ, Sutor SL, Chini CC, Yacyshyn E, Bubeck Wardenburg J, Dalton M, Chan AC, Abraham RT: Phosphorylation of Tyr319 in ZAP-70 is required for T-cell antigen receptor-dependent phospholipase Cgamma1 and Ras activation. EMBO J 1999; 18: 1832-1844.
22. Gong Q, Jin X, Akk AM, Foger N, White M, Gong G, Bubeck Wardenburg J, Chan AC: Requirement for tyrosine residues 315 and 319 within zeta chain-associated protein 70 for T cell development. J Exp Med 2001; 194: 507-518.
23. Davanture S, Leignadier J, Milani P, Soubeyran P, Malissen B, Malissen M, Schmitt-Verhulst AM, Boyer C: Selective defect in antigen-induced TCR internalization at the immune synapse of CD8 T cells bearing the ZAP-70(Y292F) mutation. J Immunol 2005; 175: 3140-3149.
24. Attrill H, Takazawa H, Witt S, Kelm S, Isecke R, Brossmer R, Ando T, Ishida H, Kiso M, Crocker PR, van Aalten DM: The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor design. Biochem J 2006; 397: 271-278.
25. Attrill H, Imamura A, Sharma RS, Kiso M, Crocker PR, van Aalten DMF: Siglec-7 undergoes a major conformational change when complexed with the- (2,8)-disialyganglioside GT1b. J Biol Chem 2006; 281: 32774-32783.
26. Angata T, Varki A: Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs: evidence for co-evolution with sialic acid synthesis pathways. J Biol Chem 2000; 275: 22127-22135.
27. Downward J, Graves JD, Warne PH, Rayter S, Cantrell DA: Stimulation of p21ras upon T-cell activation. Nature 1990; 346: 719-723.
28. Schwartz RH: Costimulation of Tlymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 1992; 71: 1065-1068.
29. Powell JD, Ragheb JA, Kitagawa-Sakakida S, Schwartz RH: Molecular regulation of interleukin- 2 expression by CD28 co-stimulation and anergy. Immunol Rev 1998; 165: 287-300.
30. Czyzyk JK, Fernsten PD, Brtva TR, Der CJ, Winfield JB: CD45 and Src-related protein tyrosine kinases regulate the T cell response to phorbol esters. Biochem Biophys Res Commun 1998; 243: 444-450.